Table 3.
Baseline demographics and characteristics by subgroup (safety analysis set)
| Characteristics | Apixaban initiators (n = 3106) | From warfarin (n = 2038) | From other NOACs (n = 1118) | P value for trend |
|---|---|---|---|---|
| Women | 1278 (41.1) | 844 (41.4) | 450 (40.3) | 0.811 |
| Age (y) | 73.6 ± 10.8 | 76.0 ± 9.0 | 74.3 ± 9.6 | <0.001 |
| Weight (kg) | 60.0 ± 12.6 (n = 2923) | 58.8 ± 12.6 (n = 1898) | 59.8 ± 12.9 (n = 1032) | 0.004 |
| Serum creatinine (mg/dL) | 0.87 ± 0.43 (n = 2914) | 0.93 ± 0.29 (n = 1855) | 0.93 ± 0.30 (n = 1007) | <0.001 |
| Creatinine clearance (mL/min) | 65.4 ± 27.0 (n = 2796) | 58.0 ± 26.0 (n = 1760) | 60.4 ± 26.0 (n = 953) | <0.001 |
| CHADS2 score | 1.9 ± 1.3 | 2.3 ± 1.4 | 2.1 ± 1.4 | <0.001 |
| CHA2DS2‐VASc score | 3.2 ± 1.7 | 3.7 ± 1.7 | 3.5 ± 1.7 | <0.001 |
| HAS‐BLED score | 1.4 ± 1.0 | 2.1 ± 1.1 | 1.7 ± 1.0 | <0.001 |
| Antiplatelet use | 534 (17.2) | 442 (21.7) | 200 (17.9) | <0.001 |
Note: Values are mean ± standard deviation or number of patients (%).
Abbreviation: NOACs, non‐vitamin K oral anticoagulants.